ACHL's logo.
Ticker Symbol: ACHL

Achilles Therapeutics Plc - ADR

$5.55 - 13-12-2024 4 p.m. ET

Exchange: NASDAQ Country: United Kingdom Currency: USD Asset Type: ADR CIK:0001830749

Company Profile

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.92
Change: -$0.02 ( -2.59%)
Days Range: $0.92 - $0.98
Beta: 0.68
52wk. High: $2.16
52wk. Low: $0.75
Ytd. Change 0.23%
50 Day Moving Average: $0.88
200 Day Moving Average: $0.94
Shares Outstanding: 40946239

Valuation

Market Cap: 3.8B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A